A comparative effectiveness program launched by Geisinger Health has reportedly slowed the rapid increase in biologic spending, according to an HFMA report. According to the report, Geisinger Health Plan's spending on biologics accounted for about 35.9 percent of its total drug spending in 2018, […]
2015 Comparative Effectiveness Research Infographic
Now in its fifth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Infographic available for download here. (Source: National Pharmaceutical […]
The Myth of Average: Infographic for Patients
Understanding which health care treatments or preventive care will work best for you is important. This infographic for patients is available for download here. (Source: National Pharmaceutical Council) […]
The Myth of Average (Health Professionals) Infographic
Understanding which health care treatments or preventative care will work best for you is important. Infographic available for download here. (Source: National Pharmaceutical Council) […]
2014 Comparative Effectiveness Research and the Environment for Health Care Decision-Making Infographic
Now in its fourth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Take a look at this infographic. (Source: National Pharmaceutical Council) […]
National Pharmaceutical Council. 2014 Comparative Effectiveness Research and Environment Health Care Decision-Making Infographic.
Or download the infographic PDF file here. […]
Health Care Decision Makers’ Use of Comparative Effectiveness Research: Report from a Series of Focus Groups
Challenging a Sacred Cow: The Top-Down Approach to Comparative Effectiveness
Blog posting by Nick Emptage, healthycriticism.com, describing CER goals, considerations (statistical sig, measured effect meaning, whether comparisons are valid). […]
Demystifying Comparative Effectiveness Research: A Case Study Learning Guide
Infographic: Is Comparative Effectiveness Research Meeting Market Demand?
Since January 2010, HTA organizations across the globe have issued nearly 1,000 CE reports. Yet just 5% of this U.S.-based research and 9% of research outside the U.S. address four high-burden conditions: non-small cell lung cancer, rheumatoid arthritis, multiple sclerosis and hepatitis C. […]
Methods in Comparative Effectiveness Research
Communicating About Comparative Effectiveness Research: A Health Affairs Symposium on the Issues
Using Comparative Effectiveness Research to Inform Policymaking
Policymakers often use the research these organizations generate to determine the content of publicly provided health benefits […]
Videos: JAMA Theme Issue on Comparative Effectiveness Research
Welcome and Opening Remarks: Phil B. Fontanarosa, M.D., M.B.A., Executive Editor, JAMA […]
Videos: JAMA Theme Issue on Comparative Effectiveness Research
Deborah Schrag, M.D., M.P.H., Dana-Farber Cancer Institute […]
Videos: JAMA Theme Issue on Comparative Effectiveness Research
Adil H. Haider, M.D., M.P.H., F.A.C.S., Johns Hopkins University School of Medicine […]
Videos: JAMA Theme Issue on Comparative Effectiveness Research
Ronald C. Chen, M.D., M.P.H., University of North Carolina at Chapel Hill […]
Videos: JAMA Theme Issue on Comparative Effectiveness Research
Anne C. Beal, M.D., M.P.H., Patient-Centered Outcomes Research Institute […]
Comparative Effectiveness Research Collaborative Initiative – Presentation from ISPOR DC
Is it possible to efficiently generate and interpret CER for newly marketed drugs in time?
Kristijan H. Kahler, PhD, RPh, Executive Director, Outcomes Research Methods & Analytics, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ISPOR Washington DC, 2012. […]
Principles for Planning and Conducting Comparative Effectiveness Research
A set of 13 best practice principles developed by a group of leading researchers could help to ensure more consistency in how comparative effectiveness research (CER) is conducted and applied in real world situations. These guiding principles were published as part of peer-reviewed study in the […]
Opportunities and Challenges for Comparative Effectiveness Pragmatic Clinical Trials in Europe, PPT
Presentation at ISPOR Europe, Nov. 2011, by Marc L. Berger, M.D., Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA […]
Personalized Medicine and Companion Diagnostics in Oncology: Challenges and Solutions, PPT
Presentation at ISPOR Europe, Nov. 2011, by Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK […]
FDAMA Section 114 and CER Master Slide Deck
Master slide deck from Tufts University which covers FDAMA Section 114 and CER […]
Role of Government in CER
Presentation from Clifford Goodman, PhD delivered at the National Comparative Effectiveness Summit, Oct. 13, 2011 […]
RCTs vs Observational Studies: The Next Great Debate in CER
Comparative Effectiveness Research: Do Employers Care? What Will They Do?
Attitudes of employers on comparative effectiveness research. […]
The State of Comparative Effectiveness Research and the Environment for Decision Making
Utilizing Health Outcomes Data to Drive Company Decision-Making: Interview With Kevin Mayo
Interview covering trends and major challenges in HEOR. […]
Comparative Cost Effectiveness and Value-Based Purchasing: Why the Pharmaceutical and Medical-Surgical Device Industries Are Embracing the Coming Market Evolution
By Josh Feldstein. This white paper examines key factors in CER, and makes specific recomendations. […]
